3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Other solid neoplasm
2
Other hematologic neoplasm
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Pancreatic Neoplasms
2
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Interventions
Cyclophosphamide
4
pembrolizumab
3
Nivolumab
3
regorafenib
2
fludarabine
2
SS1(dsFv)PE38
2
Ipilimumab
2
Hyperthermic Intraperitoneal Chemotherapy
2
Doxorubicin
2
Decitabine
2
Cisplatin
2
tislelizumab
1
sodium thiosulfate
1
sargramostim
1
entinostat
1
durvalumab
1
cemiplimab
1
bemcentinib
1
avelumab
1
atezolizumab
1
alvocidib
1
alanosine
1
X-Rays
1
Tetrahydrouridine
1
Tamoxifen
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Specimen Handling
1
Referral and Consultation
1
Radiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
bemcentinib
×
Gastrointestinal
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts